Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Group 1 - Sonnet BioTherapeutics Inc. is undergoing a transformative business combination with Rorschach I, resulting in the creation of Hyperliquid Strategies Inc., a public cryptocurrency treasury company valued at approximately $888 million [1][2] - Hyperliquid Strategies will hold around 12.6 million HYPE tokens worth $583 million and $305 million in cash [1] - The new entity will be Nasdaq-listed under a new ticker and led by Bob Diamond as Chairman and David Schamis as CEO, with participation from major crypto investors like Galaxy Digital, Pantera Capital, and D1 Capital [2] Group 2 - Sonnet will become a subsidiary of Hyperliquid Strategies and will continue its biotech research and development, including the SON-1010 project [2] - The company plans to raise $5.5 million through private placement and shareholders will receive a contingent value right (CVR) related to Sonnet's legacy biotech assets [2] - In April, Sonnet released safety results for SON-1010 in a Phase 1b/2a trial, which has now advanced to the expansion phase based on positive feedback from the Safety Review Committee [3] Group 3 - The expansion phase will study the preliminary effect of the combination treatment before moving to a Phase 2a randomized comparison with the standard of care [4] - Following the news of the business combination, SONN stock surged by 151%, reaching $12.98 [4]